Literature DB >> 3460809

Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS).

J Cummings, S Merry, N Willmott.   

Abstract

Disposition kinetics of Adriamycin (ADR), adriamycinol (AOL) and their 7-deoxyaglycones (ADR-DONE and AOL-DONE) have been studied in AKR mice bearing a s.c. growing ROS tumour after i.v. administration of 10 mg/kg. ADR and its metabolites were extracted from tissues by two different methods, separated and identified by HPLC. Tissue 7-deoxyaglycones were isolated, purified and then identified by HPLC, TLC and mass spectrometry. Kinetic profiles of ADR showed rapid equilibration of the drug with well perfused tissues but a slower and complex equilibration of the drug with the ROS tumour. Serum and tissue profiles of AOL were similar to the parent drug. From the kinetic profiles of the 7-deoxyaglycones it appeared that in the tissues their formation was rapid, with ADR-DONE always appearing first. Maximum concentrations of ADR-DONE were reached in the liver and heart only 10 min after drug administration. Estimated half lives of ADR-DONE were in liver, 1.1 hr and in heart, 2.8 hr and for AOL-DONE in liver, 5.4 hr, in heart, 5.1 hr and in serum, 4.1 hr.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3460809     DOI: 10.1016/0277-5379(86)90112-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

1.  Doxorubicin-induced cardiotoxicity.

Authors:  L Samuel
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

2.  Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Authors:  A Andersen; D J Warren; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Antibody-targeted polymer-bound drugs.

Authors:  B Ríhová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

4.  Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy.

Authors:  S Stallard; J G Morrison; W D George; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Metabolism of epidoxorubicin in animals: absence of glucuronidation.

Authors:  P A Maessen; K B Mross; H M Pinedo; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.

Authors:  J de Jong; I Klein; A Bast; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.

Authors:  W J van der Vijgh; P A Maessen; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug.

Authors:  J Cummings; C S McArdle
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.